Evidence map›Paper›PMID 42474124›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

One-Year Substantia Nigra

Calvin Coussediere, Bruno Pereira, David Devos, Stéphane Lehéricy, Patrice Peran, Elodie Durand, Carine Chassain, Jean Luc Houeto, Isabelle Benatru, Olivier Colin and 20 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Calvin CoussediereNeurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Bruno PereiraBiostatistics Unit (DRCI), Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
David DevosDepartment of Medical Pharmacology, Expert Centre of Parkinson's Disease, University of Lille, LilNCog, Lille Neuroscience and Cognition, INSERM UMR-S1172, CHU de Lille LICEND COEN Center Lille and NS-PARK/FCRIN Network, Lille, France.
Stéphane LehéricySorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225; Département de Neuroradiologie and NS-PARK/FCRIN Network; Hôpital Pitié-Salpêtrière, Paris, France.
Patrice PeranToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France.ORCID https://orcid.org/0000-0001-7200-0139
Elodie DurandNeurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Carine ChassainNeurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Jean Luc HouetoService de Neurologie, Centre Expert Parkinson, and NS-PARK/FCRIN Network, INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France.
Isabelle BenatruService de Neurologie, Centre Expert Parkinson, and NS-PARK/FCRIN Network, INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France.
Olivier ColinService de Neurologie, Centre Expert Parkinson, and NS-PARK/FCRIN Network, INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France.
Olivier RascolCentre expert Parkinson, Départements de Pharmacologie clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul INSERM, CHU de Toulouse et Université de Toulouse3, and NS-PARK/FCRIN Network, Toulouse, France.
Fabienne Ory-MagneCentre expert Parkinson, Départements de Pharmacologie clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul INSERM, CHU de Toulouse et Université de Toulouse3, and NS-PARK/FCRIN Network, Toulouse, France.
Christine Brefel-CourbonCentre expert Parkinson, Départements de Pharmacologie clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul INSERM, CHU de Toulouse et Université de Toulouse3, and NS-PARK/FCRIN Network, Toulouse, France.
Anne Doé de MaindrevilleDepartment of Neurology, CHU Reims, and NS-PARK/FCRIN Network, Reims, France.
Marie VidailhetDépartement de Neurologie CIC Neurosciences, Hôpital Pitié-Salpêtrière, and NS-PARK/FCRIN Networ, Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Paris, France.
Jean-Christophe CorvolDépartement de Neurologie CIC Neurosciences, Hôpital Pitié-Salpêtrière, and NS-PARK/FCRIN Networ, Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Paris, France.
Solène FrismandDepartment of Neurology, Nancy University Hospital Center, and NS-PARK/FCRIN Network, Nancy, France.
Emmanuelle SchmittDepartment of Neuroradiology, Nancy University Hospital Center, Nancy, France.
Luc DefebvreDepartment of Movement Disorders, Inserm 1172, University of Lille and NS-PARK/FCRIN Network, Lille, France.
Nicolas CarriereDepartment of Movement Disorders, Inserm 1172, University of Lille and NS-PARK/FCRIN Network, Lille, France.
Wassilios G MeissnerCHU Bordeaux, Service de Neurologie - Maladies Neurodégénératives, IMNc and NS-PARK/FCRIN Network, Bordeaux, France.ORCID https://orcid.org/0000-0003-2172-7527
Thomas BoraudCHU Bordeaux, Service de Neurologie - Maladies Neurodégénératives, IMNc and NS-PARK/FCRIN Network, Bordeaux, France.
Philippe RemyCentre Expert Parkinson CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Université PSL, and NS-PARK/FCRIN Network, Créteil, France.
Elena MoroUniversité Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France.
Stéphane ThoboisUniv Lyon, Lyon Neuroscience Research Center (CRNL), CNRS UMR 5292, INSERM U1028, Bron, France.
Christian GenyDepartment of Neurology, CIC, Institut d'Imagerie Fonctionnelle Humaine, Montpellier University Hospital and NS-PARK/FCRIN Network, Montpellier, France.
Jean-Marie BonnyINRAE, UR QuaPA, Université Clermont Auvergne, Saint-Genès-Champanelle, France.ORCID https://orcid.org/0000-0003-2858-7459
Franck DurifNeurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
Ana MarquesNeurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
MPI‐R2* study group

Funding

Association France ParkinsonFédération pour la Recherche sur le Cerveau (FRC)" and "NS-PARK F-CRIN Network (French Clinical Research Infrastructure Network)French Ministry of Health (Programme Hospitalier de Recherche Clinique, PHRC) PHRC-16-005
6 · The paper itself

Abstract

backgroundMagnetic resonance imaging (MRI) relaxometry using

objectivesThe goal was to assess 1-year longitudinal

methodsIn this prospective multicenter study, 95 PD patients and 65 age- and sex-matched HC underwent 3 T MRI and clinical evaluation at baseline and 1 year. PD patients were stratified by disease duration (<5, 5-10, 10-15, >15 years).

resultsSN

conclusionsSN

Indexed as

Parkinson DiseaseSubstantia NigraAgedDisease ProgressionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedProspective Studiesbiomarkerlongitudinal studyMRI relaxometryParkinson's diseaseR2*substantia nigra

Identifiers

PMID42474124
PMCPMC13518270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.